Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GNLX
stocks logo

GNLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.218
-16.03%
--
--
-0.216
+2.86%
--
--
-0.226
+13%
Estimates Revision
The market is revising No Change the revenue expectations for Genelux Corporation (GNLX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 37.98%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+37.98%
In Past 3 Month
Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.50 USD with a low forecast of 16.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.50 USD with a low forecast of 16.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.650
sliders
Low
16.00
Averages
22.50
High
31.00
Current: 4.650
sliders
Low
16.00
Averages
22.50
High
31.00
Titan Partners
Boris Peaker
initiated
$20
2025-10-31
Reason
Titan Partners
Boris Peaker
Price Target
$20
2025-10-31
initiated
Reason
Titan Partners analyst Boris Peaker initiated coverage of Genelux with a Buy rating and $20 price target. The development-stage biotechnology company has an oncolytic viral therapy in a pivotal Phase 3 study, OnPrime, in ovarian cancer with data anticipated in the first half of 2026, notes the analyst, who says the firm's 12-18 month price target assumes positive results from OnPrime. Updates from ongoing studies in NSCLC and SCLC by year-end can act as additional catalysts, but are not factored into the firm's valuation, the analyst added.
Lake Street
Chad Messer
initiated
$16
2025-10-21
Reason
Lake Street
Chad Messer
Price Target
$16
2025-10-21
initiated
Reason
Lake Street analyst Chad Messer initiated coverage of Genelux with a Buy rating and $16 price target. The pivotal readout for olvimulogene nanivacirepvec, or olvi-vec, in ovarian cancer, due in the first half of 2026, could "revolutionize treatment of this deadly indication," the analyst tells investors. The firm forecasts peak U.S. sales of $2B in this indication alone, but also notes two more shots on goal in lung cancer that it contends "could boost strategic interest."
Maxim
Maxim
NULL -> Buy
maintain
$10 -> $20
2025-10-21
Reason
Maxim
Maxim
Price Target
$10 -> $20
2025-10-21
maintain
NULL -> Buy
Reason
Maxim raised the firm's price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating on the shares. The firm is lowering its risk adjustment for olvimulogene nanivacirepvec after the FDA's acceptance of the BLA resubmission from Replimune (REPL) for RP1 plus nivolumab for the treatment of advanced melanoma progressing on PD-1 based therapy, the analyst tells investors.
Lucid Capital
NULL -> Buy
initiated
$10
2025-07-21
Reason
Lucid Capital
Price Target
$10
2025-07-21
initiated
NULL -> Buy
Reason
Lucid Capital initiated coverage of Genelux with a Buy rating and $10 price target. Genelux is a late clinical-stage biotechnology company focused on utilizing oncolytic viral immunotherapies for the treatment of cancer, the analyst tells investors in a research note. The firm sees a "low hanging fruit" opportunity for lead candidate Olvi-Vec in platinumresistant/refractory ovarian cancer.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$30
2025-03-31
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$30
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$30
2025-03-25
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$30
2025-03-25
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Genelux Corp (GNLX.O) is -5.19, compared to its 5-year average forward P/E of -12.40. For a more detailed relative valuation and DCF analysis to assess Genelux Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.40
Current PE
-5.19
Overvalued PE
1.03
Undervalued PE
-25.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.62
Undervalued EV/EBITDA
-1.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4459.23
Current PS
0.00
Overvalued PS
19294.26
Undervalued PS
-10375.80
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GNLX News & Events

Events Timeline

(ET)
2025-11-05
17:58:27
Genelux Announces Q3 Earnings Per Share of 21 Cents, Matching Expectations
select
2025-08-07 (ET)
2025-08-07
17:58:49
Genelux reports Q2 EPS (20c), consensus (22c)
select
2025-07-07 (ET)
2025-07-07
07:05:31
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26Globenewswire
Genelux CEO to Participate in Piper Sandler Healthcare Conference, Showcasing New Therapy Progress
  • Executive Participation: Genelux President and CEO Thomas Zindrick will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, in New York, showcasing the company's latest advancements in oncolytic immunotherapy, which is expected to attract investor interest.
  • Clinical Trial Progress: Olvi-Vec is undergoing multiple clinical trials, including a Phase 3 registrational trial for platinum-resistant ovarian cancer and a Phase 2 trial for non-small-cell lung cancer, demonstrating the company's potential in developing new cancer treatment options that could enhance future market performance.
  • Exploration of Chinese Market: Olvi-Vec is also being evaluated in a Phase 1b trial in China for recurrent small-cell lung cancer, and this international expansion strategy may help the company penetrate global markets and enhance its brand influence.
  • Technological Platform Advantage: The CHOICE™ platform supports the development of various immunotherapeutic products, bolstering Genelux's innovation capabilities and competitive edge in the highly competitive biopharmaceutical industry.
[object Object]
Preview
9.5
11-06Newsfilter
Genelux Corporation Announces Financial Results for Q3 2025 and Shares Business Updates

  • Lung and Ovarian Cancer Trials: Genelux Corporation is advancing its Olvi-Vec treatment in ongoing Phase 3 trials for platinum-resistant/refractory ovarian cancer, with topline data expected in the second half of 2026, and interim data from lung cancer studies anticipated in Q4 2025.

  • Financial Overview: As of September 30, 2025, Genelux reported $21.0 million in cash and equivalents, with a net loss of $8.0 million for the third quarter, reflecting increased research and development expenses.

  • Olvi-Vec Mechanism: Olvi-Vec is designed to directly kill cancer cells and stimulate an immune response, with potential applications in various solid tumors, including lung cancer, where it is being tested in combination with standard therapies.

  • Regulatory Pathway: The company believes that data from its ongoing trials could support traditional regulatory approval, contingent on demonstrating a meaningful progression-free survival advantage without compromising overall survival.

[object Object]
Preview
4.0
10-21Benzinga
Lake Street Begins Coverage of Genelux with a Buy Rating and Sets Price Target at $16

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.

  • Exclusive Content: The platform features exclusive stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing insights and strategies.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information necessary to make informed decisions and capitalize on market opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Genelux Corp (GNLX) stock price today?

The current price of GNLX is 4.65 USD — it has increased 0 % in the last trading day.

arrow icon

What is Genelux Corp (GNLX)'s business?

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

arrow icon

What is the price predicton of GNLX Stock?

Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.50 USD with a low forecast of 16.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Genelux Corp (GNLX)'s revenue for the last quarter?

Genelux Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Genelux Corp (GNLX)'s earnings per share (EPS) for the last quarter?

Genelux Corp. EPS for the last quarter amounts to -0.21 USD, increased 10.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Genelux Corp (GNLX)'s fundamentals?

The market is revising No Change the revenue expectations for Genelux Corporation (GNLX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 37.98%.
arrow icon

How many employees does Genelux Corp (GNLX). have?

Genelux Corp (GNLX) has 24 emplpoyees as of December 05 2025.

arrow icon

What is Genelux Corp (GNLX) market cap?

Today GNLX has the market capitalization of 176.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free